MU
Micron Technology
-- 86.605 TSLA
Tesla
-- 429.810 NVDA
NVIDIA
-- 131.860 QUBT
Quantum Computing
-- 15.802 NUKK
Nukkleus
-- 51.410 
New 8K
$Bionomics (BNOX.US)$ Supreme Court of New South Wales approves Bionomics’ re-domiciliation
Adelaide, Australia and Cambridge, Mass., December 16, 2024 (GLOBE NEWSWIRE) – Bionomics Limited (Nasdaq: BNOX) (“Bionomics” or the “Company”) is pleased to announce that the Supreme Court of New South Wales, Australia (“Court”) has today made orders approving the scheme of arrangement in relation to the Company’s proposed re-domiciliation from Australia to the United States (“Scheme”), under which Neuphoria Therapeutics Inc., a Delaware corporation (“Neuphoria”), will become the ultimate parent company of Bionomics Limited following the implementation of the Scheme.
A copy of the Court’s orders with respect to the Scheme was lodged with the Australian Securities & Investments Commission following the Court hearing, at which time the Scheme became legally effective. Bionomics’ ADSs will continue to trade on Nasdaq until the implementation date (December 23, 2024 (New York time)).
Bionomics shareholders who hold shares on the record date for the Scheme (5:00pm Sydney time on Tuesday, December 17, 2024) will be entitled to receive the Scheme consideration (in accordance with the terms of the Scheme as set out in Section 6 of the Scheme Booklet dated November 11, 2024 (“Scheme Booklet”)). The Scheme consideration will be paid to Scheme Shareholders (as defined in the Scheme Booklet) on the implementation date.
Shares of Neuphoria are expected to begin trading on Nasdaq under the symbol “NEUP” on December 24, 2024 or as soon as possible thereafter.
Adelaide, Australia and Cambridge, Mass., December 16, 2024 (GLOBE NEWSWIRE) – Bionomics Limited (Nasdaq: BNOX) (“Bionomics” or the “Company”) is pleased to announce that the Supreme Court of New South Wales, Australia (“Court”) has today made orders approving the scheme of arrangement in relation to the Company’s proposed re-domiciliation from Australia to the United States (“Scheme”), under which Neuphoria Therapeutics Inc., a Delaware corporation (“Neuphoria”), will become the ultimate parent company of Bionomics Limited following the implementation of the Scheme.
A copy of the Court’s orders with respect to the Scheme was lodged with the Australian Securities & Investments Commission following the Court hearing, at which time the Scheme became legally effective. Bionomics’ ADSs will continue to trade on Nasdaq until the implementation date (December 23, 2024 (New York time)).
Bionomics shareholders who hold shares on the record date for the Scheme (5:00pm Sydney time on Tuesday, December 17, 2024) will be entitled to receive the Scheme consideration (in accordance with the terms of the Scheme as set out in Section 6 of the Scheme Booklet dated November 11, 2024 (“Scheme Booklet”)). The Scheme consideration will be paid to Scheme Shareholders (as defined in the Scheme Booklet) on the implementation date.
Shares of Neuphoria are expected to begin trading on Nasdaq under the symbol “NEUP” on December 24, 2024 or as soon as possible thereafter.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
小强不死 : @Trytosaveabit Sorry, I am a newbie. May I ask if this news is bullish or bearish?
Trytosaveabit OP 小强不死 : IMO it’s kinda bullish! It’s another step towards becoming more bullish as they move closer to the move to the U.S.